Business Development

Arcturus Business Development Opportunities

Arcturus Therapeutics is actively engaged in partnering discussions. Please contact
BD@ArcturusRx.com regarding any business development opportunities.
Partnered RNA Medicines

Partnered RNA Medicines

LUNAR®-HBV
In October 2017, Arcturus entered into a partnership with Janssen, a Johnson & Johnson company, to develop and commercialize nucleic acid-based drug products for the treatment of specified diseases, including HBV, using Arcturus’ LUNAR® lipid-mediated delivery platform and UNA oligomer chemistry. Under the agreement, facilitated by J&J Innovation, Arcturus received an upfront cash payment and will receive R&D support, as well as pre-clinical, development, and sales milestone payments, and royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program.
COVID-19 Vaccine
In March 2020, we partnered with Duke-NUS Medical School to develop a COVID-19 vaccine for the Singapore Economic Development Board (“EDB”) based on the Company’s STARR Technology and designated the vaccine candidate LUNAR®-COV19 (ARCT-021). Duke-NUS Medical School is a graduate entry medical school in Singapore, established in 2005 through a partnership between Duke University School of Medicine and the National University of Singapore (“NUS”).
COVID-19 Vaccine
In October 2020, we were awarded a grant from the EDB to support the further development of our LUNAR®-COV19 vaccine candidate. In November 2020, we announced a manufacturing support agreement with the EDB.
COVID-19 Vaccine
In August 2020, we entered into a definitive Supply Agreement (the “Supply Agreement”) with the Israeli Ministry of Health (“MOH”) which provides for the supply of ARCT-021 to the MOH. The MOH has elected to reserve delivery by us of doses of ARCT-021. The Supply Agreement also provides the MOH with the right to elect to purchase additional doses of ARCT-021 upon notice to us prior to specified dates at specified purchase prices.
LUNAR®-NASH
In December 2016, Arcturus entered into a partnership with Takeda to develop RNA-based therapeutic candidates for the treatment of NASH and other GI-related disorders, utilizing Arcturus’ wholly owned therapeutic delivery platform, LUNAR®.
LUNAR®-GSDIII and LUNAR®RARE
In October 2015, Arcturus has partnered with Ultragenyx Pharmaceutical, Inc. to develop RNA medicines that treat rare diseases. This collaboration combines Arcturus’ expertise in RNA medicines with Ultragenyx’ proven ability in rare disease drug development. In this partnership, Arcturus is exploiting the versatility of our proprietary Lipid-enabled and Unlocked Nucleic Acid modified RNA (LUNAR®) lipid-mediated delivery platform to design and optimize mRNA medicines for rare disease targets. These medicines will be developed and commercialized by Ultragenyx. Ultragenyx has advanced LUNAR®-GSDIII into clinical development.
In August 2021, we announced an agreement with Vingroup, to establish a manufacturing facility in Vietnam for the manufacture of Arcturus’ investigational COVID-19 vaccines, for sale and use within Vietnam. Under the agreement, Vinbiotech will build out a manufacturing facility in Vietnam, and we will provide to Vinbiotech access to proprietary technologies and processes for the manufacture of Arcturus’ investigational COVID-19 vaccines. The license and technology transfer applies toward drug product manufacturing.
Internal Programs

Internal Programs

LUNAR®-OTC
The LUNAR®-OTC (ARCT-810) development program addresses ornithine transcarbamylase (“OTC”) deficiency, a rare, genetic disease caused by mutations in the OTC gene that lead to dysfunctional or deficient OTC levels. Our LUNAR®-OTC development candidate, ARCT-810, uses our LUNAR® platform to deliver normal OTC mRNA into liver cells, where OTC is produced and functions, to produce normal functioning OTC with possible disease-modifying effects. Our LUNAR®-OTC approach has the potential to treat the underlying defect that causes the debilitating symptoms of OTC deficiency, rather than mitigating symptoms by sequestering ammonia. LUNAR®-OTC has received orphan drug designation from the FDA for treatment of OTC deficiency. LUNAR®-OTC has received approval from the UK Health Research Authority to initiate a Phase 2 clinical study. Worldwide development and commercialization rights to ARCT-810 are entirely held by Arcturus.
LUNAR®-CF (ARCT-032 Grant by CFF)
ARCT-032 (LUNAR®-CF) LUNAR®- program addresses cystic fibrosis lung disease, a progressive lung disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (“CFTR”) gene. In December 2020, we announced the selection and advancement of ARCT-032 as a development candidate for treatment of cystic fibrosis. ARCT-032 uses our LUNAR® platform to deliver codon-optimized CFTR mRNA into airway epithelial cells. This allows airway cells to produce functional CFTR protein using their native translational machinery and protein trafficking pathways. This approach has the potential to treat the underlying defect that causes CF lung disease, regardless of what mutation type a patient has. The Cystic Fibrosis Foundation (“CFF”) has recognized the potential of the LUNAR®-CF program and has partnered with us to develop this important therapy. ARCT-032 represents the first LUNAR®-based mRNA therapeutic that will be delivered by the inhaled route, offering direct delivery to the affected airways with the potential to restore functional CFTR. We have announced selection of a development candidate and plan to initiate a CTA in 2022.
Technology Platforms

Technology Platforms

Arcturus’ versatile RNA therapeutics and LNP Delivery Systems platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). These technologies are potentially available for licensing as part of a collaboration. Please contact BD@ArcturusRx.com regarding any business development opportunities.
  • LUNAR® LNP Lipid-mediated delivery
  • STARR™ mRNA Technology
  • RNA Manufacturing Expertise

Partnered RNA Medicines

LUNAR®-HBV
In October 2017, Arcturus entered into a partnership with Janssen, a Johnson & Johnson company, to develop and commercialize nucleic acid-based drug products for the treatment of specified diseases, including HBV, using Arcturus’ LUNAR® lipid-mediated delivery platform and UNA oligomer chemistry. Under the agreement, facilitated by J&J Innovation, Arcturus received an upfront cash payment and will receive R&D support, as well as pre-clinical, development, and sales milestone payments, and royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program.
COVID-19 Vaccine
In March 2020, we partnered with Duke-NUS Medical School to develop a COVID-19 vaccine for the Singapore Economic Development Board (“EDB”) based on the Company’s STARR Technology and designated the vaccine candidate LUNAR®-COV19 (ARCT-021). Duke-NUS Medical School is a graduate entry medical school in Singapore, established in 2005 through a partnership between Duke University School of Medicine and the National University of Singapore (“NUS”).
COVID-19 Vaccine
In October 2020, we were awarded a grant from the EDB to support the further development of our LUNAR®-COV19 vaccine candidate. In November 2020, we announced a manufacturing support agreement with the EDB.
COVID-19 Vaccine
In August 2020, we entered into a definitive Supply Agreement (the “Supply Agreement”) with the Israeli Ministry of Health (“MOH”) which provides for the supply of ARCT-021 to the MOH. The MOH has elected to reserve delivery by us of doses of ARCT-021. The Supply Agreement also provides the MOH with the right to elect to purchase additional doses of ARCT-021 upon notice to us prior to specified dates at specified purchase prices.
LUNAR®-NASH
In December 2016, Arcturus entered into a partnership with Takeda to develop RNA-based therapeutic candidates for the treatment of NASH and other GI-related disorders, utilizing Arcturus’ wholly owned therapeutic delivery platform, LUNAR®.
LUNAR®-GSDIII and LUNAR®RARE
In October 2015, Arcturus has partnered with Ultragenyx Pharmaceutical, Inc. to develop RNA medicines that treat rare diseases. This collaboration combines Arcturus’ expertise in RNA medicines with Ultragenyx’ proven ability in rare disease drug development. In this partnership, Arcturus is exploiting the versatility of our proprietary Lipid-enabled and Unlocked Nucleic Acid modified RNA (LUNAR®) lipid-mediated delivery platform to design and optimize mRNA medicines for rare disease targets. These medicines will be developed and commercialized by Ultragenyx. Ultragenyx has advanced LUNAR®-GSDIII into clinical development.
In August 2021, we announced an agreement with Vingroup, to establish a manufacturing facility in Vietnam for the manufacture of Arcturus’ investigational COVID-19 vaccines, for sale and use within Vietnam. Under the agreement, Vinbiotech will build out a manufacturing facility in Vietnam, and we will provide to Vinbiotech access to proprietary technologies and processes for the manufacture of Arcturus’ investigational COVID-19 vaccines. The license and technology transfer applies toward drug product manufacturing.

News & Events

November 22, 2021
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 8, 2021
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
October 25, 2021
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
October 21, 2021
Arcturus Therapeutics Announces Leadership Appointments
October 20, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
September 22, 2021
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
September 22, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
September 8, 2021
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
September 7, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
August 9, 2021
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
August 3, 2021
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
August 2, 2021
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
August 2, 2021
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
July 28, 2021
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
July 26, 2021
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
July 6, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
June 9, 2021
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
May 10, 2021
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data